Pharmacology letters accelerated communication inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes

Life Sciences

Volumn 63, Issue 8, 1998, Pages 119-123

  Zhai, Suoping ^a,b   Dai, Renke ^c   Wei, Xiaoxiong ^c   Friedman, Fred K ^c   Vestal, Robert E ^a,b,d  

^a Boise VA Medical Center   (United States)

^b IDAHO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CYP1A2; Flavonoids; Galangin; Human liver microsomes; Inhibition; Methoxyresorufin; Phytochemicals

Indexed keywords

CYTOCHROME P450 ISOENZYME; FLAVONOID; 3 HYDROXYFLAVONE; 3-HYDROXYFLAVONE; CYTOCHROME P450; CYTOCHROME P450 1A2; ENZYME INHIBITOR; FLAVONE; GALANGIN; ISOENZYME; METHOXYRESORUFIN O DEMETHYLASE; METHOXYRESORUFIN-O-DEMETHYLASE; OXIDOREDUCTASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIVER MICROSOME METABOLISM; PHYTOCHEMISTRY; ADULT; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; LIVER MICROSOME;

ADULT; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; FLAVONOIDS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; OXIDOREDUCTASES;

EID: 0032541119     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 1. B. HAVSTEEN, Biochem. Pharmacol. 32 1141-1148 (1983).
2. 2. F.V. SO, N. GUTHRIE, A.F. CHAMBERS, M. MOUSSA, and K.K. CARROLL, Nutr. Cancer 26 167-181 (1996).
3. 3. L.W. WATTENBERG, Cancer Res. 52 2085-2091 (1992).
4. 4. K.A. STEINMETZ and J.D. POTTER, Cancer Causes Control 2 427-442 (1991).
5. 5. F.K. FRIEDMAN, D. WEST, T. SUGIMURA, and H.V. GELBOIN, Pharmacology 31 203-207 (1985).
6. 6. M.T. HUANG, E.F. JOHNSON, U. MULLER-EBERHARD, D.R. KOOP, M.J. COON, and A.H. CONNEY, J. Biological Chem. 256 10897-10901 (1981).
7. 7. I.B. TSYRLOV, V. M. MIKHAILENKO, and H.V.GELBOIN, Biochim. Biophys. Acta. 1205 325-335 (1994).
8. 8. M.T. OBERMEIER, R.E. WHITE, and C.S. YANG, Xenobiotica 25 575-584 (1995).
9. 9. K. KAWAJIRI, K. NAKACHI, K. IMAI, J. WATANABE, and S. HAYASHI, Crit. Rev. Oncol. Hematol. 14 77-87 (1993).
10. 10. K. BROSEN, Clin. Pharmacokinet. 29 20-25 (1995)
11. 11. F.P. GUENGERICH, Chem. Res. Toxicol. 4 391-406 (1991).
12. 12. M.E. MCMANUS, W.M. BURGESS, M.E. VERONESE, A. HUGGETT, L.C. QUATTROCHI, and R.H. TUKEY, Cancer Res. 50 3367-3376 (1990).
13. 13. T.J. SMITH, Z. GUO, F.P. GUENGERICH, and C. S. YANG, Carcinogenesis 17 809-813 (1996).
14. 14. R.J. TURESKY, N.P. LANG, M.A. BUTLER, C.H. TEITEL, and F.F. KADLUBAR, Carcinogenesis 12 1839-1845 (1991).
15. 15. M.H. SIESS, J. LECLERC, M-C CANIVENC-LAVIER, P. RAT, and M. SUSCHETET, Toxicol. Appl. Pharmacol. 130 73-78 (1995).
16. 16. M.H. SIESS, A.M. LE-BON, M. SUSCHETET, and P. RAT, Food Addit. Contain. 7 S178-S181 (1990).
17. 17. U. FUHR, K. KLITTICH, and A.H. STAIB, Br. J. Clin. Pharmcol. 35 431-436 (1993).
18. 18. M.D. BURKE, S. THOMPSON, C.R. ELCOMBE, J. HALPERT, T. HAAPANTA, and R.T. MAYER, Biochem. Pharmacol. 34 3337-3345 (1985).
19. 19. I.B. TSYRLOV, I.S. GOLDFARB, and H.V. GELBOIN, Arch. Biochem. Biophys. 2 259-266 (1993)
20. 20. R. DAI, K.A. JACOBSON, R.C. ROBINSON, and F.K. FRIEDMAN, Life Sci. 61 PL75-80 (1997).
21. 21. M. SHOU, J. GROGAN, J.A. MANCEWICZ, K.W. KRAUSZ, F.J. GONZALEZ, H.V. GELBOIN, and K.R. KORZEKWA, Biochemistry 33 6450-6455 (1994)